24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
As in Adults, Minority Kids Hit Hardest by COVID-19Simple Test Shows Which Face Masks Are BestBeware of Hand Sanitizers Containing MethanolWhat Athletes Should Know About COVID-19, Heart Damage and Working OutCOVID-19 Causing More Stress in America Than Other Nations: SurveyWill Your Kid Play School Sports This Fall? Here's Some Guidance on Doing It SafelyScientists Call for Broader Use of Faster COVID TestsTwo Common Nutrients Might Keep Vertigo at BayPeople Are Dying, Going Blind After Drinking Hand Sanitizer, CDC WarnsMore Social Media Use, More Fake COVID NewsSkip the 'Maskne,' Not the MaskObesity Ups Odds for Severe COVID-19, But Age MattersSeven States Join Pact to Speed Coronavirus TestingStudy Casts Doubt on Value of Cholesterol DrugsCOVID-19 Fears Had Sick, Injured Americans Avoiding ERsCancer Diagnoses Plunge as Americans Avoid Screening During PandemicMysterious Paralyzing Illness in Kids Is Set to Return, CDC WarnsMany Older Americans Staying Strong in the PandemicCoronavirus Cases Now Climbing in the MidwestCould the First Drug That Slows Arthritis Be Here?Schools Can Reopen Safely If Precautions in Place, Australian Study ShowsFace Masks, Yes, But Don't Forget Hand-Washing TooEven With PPE, Risk of COVID-19 Still High for Frontline WorkersCoronavirus Pandemic Becoming Far More Widespread, Birx SaysGuard Against Lyme Disease This SummerKids 'Efficient' Transmitters as COVID-19 Raced Through a Georgia Summer CampCollege Students Will Need COVID Tests Every 2-3 Days for Campus Safety: StudyAHA News: Sustained High Blood Pressure May Damage Brain VesselsAnother Side Effect of COVID-19 -- Lasting Hearing Problems?Pandemic Could Complicate Hurricane SeasonStudy Reveals How Coronavirus Travels IndoorsNew Study Sheds Doubt on Notion Kids Aren't COVID-19 SpreadersAHA News: Are Virtual Doctor Visits Safe for Discharged Heart Failure Patients?Double Lung Transplants Save Lives of Sickest COVID PatientsGynecological Cancers Not a Risk for Severe COVID-19: Study11 States Could Face ICU Doc Shortages as Coronavirus Cases SurgeWildfire Pollution Puts Kidney Patients at RiskAmerica's Progress Against Early Cardiovascular Death Is SlowingAHA News: 5 Easy Ways to Keep Tabs on Heart HealthGene Study Shows How Coronavirus Swept Through the Diamond PrincessOne Disease Mosquitoes Don't Spread: CoronavirusU.S. Coronavirus Death Toll Surges Past 150,000Do Bedbugs Dirty the Air Inside Your Home?AHA News: New Test May Predict Who Develops Certain Type of Heart FailureLess Smoking, Drinking Means Fewer Hip Fractures for AmericansYet Another Study Finds Vaccines Are SafeCommon Diabetes Meds Linked to Higher Odds for a Serious ComplicationSurvivors' COVID Antibodies May Provide a Powerful GiftConcussion Ups Odds for Many Brain ConditionsFinal Coronavirus Vaccine Trials Get Underway
Questions and AnswersLinks
Related Topics

Diabetes

Implant Approved to Improve Symptoms in Advanced Heart Failure


HealthDay News
Updated: Aug 19th 2019

new article illustration

MONDAY, Aug. 19, 2019 (HealthDay News) -- The Barostim Neo System was granted U.S. Food and Drug Administration approval to treat symptoms of patients with advanced heart failure who are not candidates for treatment with other devices such as cardiac resynchronization therapy, the agency announced on Friday.

The device includes a pulse generator implanted below a patient's clavicle and connected to a lead attached to the carotid artery. A physician tests and programs the device after implantation. The Barostim Neo System delivers electrical impulses to baroreceptors to ultimately inhibit production of stress-related hormones and reduce heart failure symptoms. Indications for treatment with the device include regular heart rhythm, not being a candidate for cardiac resynchronization therapy, and left ventricular ejection fraction of ≤35 percent. Contraindications include anatomy that could impair device implantation, certain nervous system disorders, uncontrolled and symptomatic slow heart rate, atherosclerosis, and a known allergy to silicone or titanium.

Approval of the device was based on data from a prospective, multicenter, two-arm, randomized clinical trial of 408 patients with advanced heart failure. All patients received guideline-directed medical therapy and medication, and 125 patients also received the Barostim Neo System implant. Those who received the device improved in six-minute walking tests and reported improvements in quality of life.

Potential complications from the device or implantation include infection, reoperation, low blood pressure, nerve damage, surgical or anesthetic complications, allergic reaction, arterial damage, heart failure exacerbation, stroke, and death. The FDA is requiring the manufacturer to conduct a postapproval study on the device's ability to prolong life and reduce the need for hospitalization.

Approval was granted to CVRx.

More Information